Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
Pandemics and Biosecurity
9JUN

US widens Ebola ban to green-card holders

3 min read
09:58UTC

HHS extended its 30-day Ebola entry ban to green-card holders on 5 June, while the treaty annex meant to tie data-sharing to vaccine access stayed deadlocked ahead of July talks.

ScienceDeveloping
Key takeaway

DRC shares Bundibugyo sequence data now while the annex guaranteeing access stays deadlocked into July.

The US Department of Health and Human Services (HHS), the federal department overseeing the CDC, expanded its 30-day Ebola entry ban on 5 June to cover green-card holders, lawful permanent residents 1. The restriction has been in force since 18 May against travellers from DRC, Uganda and South Sudan and runs to about 17 June, so it has widened rather than expired. DRC's health minister called it discriminatory and unsupported by science, and Kinshasa is negotiating an early lift 2. A counter-case exists: states may reasonably screen at the border during an emergency, and a Ugandan traveller with a recent United Arab Emirates (UAE) history did surface in the case data, though the UAE confirmed on 3 June it had found no onward transmission 3.

The restriction lands while the treaty meant to govern moments like this stays stuck. The WHO Pandemic Agreement's Pathogen Access and Benefit-Sharing annex, PABS, the rule tying rapid pathogen-data sharing by source countries to guaranteed access to the vaccines and treatments derived from it, was deferred at the World Health Assembly and now waits on the seventh negotiating session, IGWG7 (the Intergovernmental Working Group), 6 to 17 July 4. WHO cannot open the agreement for signature until member states adopt the annex.

DRC shows the mechanism live right now. Kinshasa is sharing Bundibugyo sequence data in real time, the genome already confirmed distinct from the 2007 and 2012 strains, while receiving no treaty-guaranteed access to whatever those sequences help produce. DRC is paying into a system whose July deadline arrives months after the vaccines its data informs. The gap the annex exists to close is running live, in one country, this month.

Deep Analysis

In plain English

The US government imposed a travel ban in May on people from DRC, Uganda and South Sudan , three countries connected to this Ebola outbreak. On 5 June they expanded it to include green-card holders, meaning even people who live legally in the US and were travelling to those countries now face restrictions on returning. The World Health Organisation says travel bans don't stop Ebola , which needs direct contact with infected bodily fluids to spread , and actually make outbreaks worse by blocking health workers and disrupting supply chains. DRC's health minister called it discriminatory. Separately, a global treaty that was supposed to guarantee that countries like DRC get fair access to vaccines when they share disease data is still deadlocked in negotiations, with the next attempt scheduled for July.

Deep Analysis
Root Causes

The PABS deadlock has a structural root cause that predates the current outbreak: roughly 100 LMIC member states demand that rapid pathogen-data sharing be contractually linked to guaranteed access to vaccines and treatments derived from those sequences, while high-income bloc states, protecting pharmaceutical IP arrangements and open-sequence-data norms, have refused to make vaccine access legally binding.

DRC is currently demonstrating the LMIC position in real time: it shared Bundibugyo sequence data under existing surveillance norms, vaccine investment arrived via CEPI and GAVI, and DRC nationals simultaneously face a US entry ban.

The green-card expansion by HHS has a domestic legal root cause separate from the epidemiology: the 18 May order's original exclusion of lawful permanent residents was challenged on due-process grounds under the Fifth Amendment, and the expansion to include them likely reflects administration legal advice that the original order's carve-out was inconsistent with the public-health emergency rationale.

Escalation

The green-card expansion represents an escalation from the 18 May entry ban : extending to lawful permanent residents means the restriction now covers a class of people with established legal ties to the US, raising constitutional challenge risk and creating a stronger diplomatic friction point.

The ban's ~17 June expiry creates a near-term decision point: extend, allow to lapse, or replace with a monitoring framework. Kinshasa's active negotiation for early lifting suggests a deal on enhanced screening in lieu of the ban is the most probable outcome, but the outcome depends on outbreak trajectory over the next eight days.

What could happen next?
  • Risk

    The PABS deadlock at IGWG7 (6-17 July) runs in parallel with the DRC outbreak: if July produces no text, the full WHO Pandemic Agreement cannot open for signature, and the current outbreak provides the clearest demonstration yet of the equity gap it was designed to close.

    Short term · Assessed
  • Consequence

    The entry ban's inclusion of green-card holders creates a constitutional challenge pathway and a diplomatic friction point with Kinshasa that may complicate US-led outbreak response coordination, including the US-led FIFA World Cup screening protocols announced 28 May.

    Immediate · Assessed
  • Precedent

    The PABS negotiating bloc's real-world illustration , DRC sharing sequence data, then facing a US travel ban , may harden LMIC positions at IGWG7 rather than create goodwill, making a July breakthrough less rather than more likely.

    Short term · Assessed
First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

World Health Organization· 9 Jun 2026
Read original
Different Perspectives
World Health Organization
World Health Organization
WHO's DON606 recalibration to confirmed-only reporting gives the clean baseline the CDC model rests on, but the apparent fall from 1,040 to 534 carries misinterpretation risk WHO communications have not pre-empted. The PABS deadlock ahead of IGWG7 and continuing MBP134/remdesivir assessment without authorisation make WHO the body most able to accelerate the two decisions that could change the outbreak's trajectory.
European Union (ECDC)
European Union (ECDC)
ECDC's Week 23 CDTR tracked four simultaneous non-Ebola signals: the Dermatophilus congolensis novel-transmission cluster across France, Germany and Spain; a 4.2-fold malaria surge in Mayotte; the Salmonella ST2045 multi-country cluster; and two new Saudi MERS cases. The continental early-warning layer is carrying a full multi-pathogen picture while Bundibugyo dominates headlines.
Uganda
Uganda
Uganda's 19 confirmed cases are concentrated in Kampala and Wakiso, an urban cluster that applied the 2022 Sudan-ebolavirus playbook; the Bwera border laboratory shortens cross-border confirmation to same-day. Uganda's regulatory authority must co-sign before MBP134 or remdesivir can dose any patient.
Democratic Republic of the Congo
Democratic Republic of the Congo
Kinshasa shares Bundibugyo sequence data in real time with no treaty-guaranteed access to the vaccines that data informs, and its health minister called the US entry ban discriminatory while negotiating an early lift. DRC accounts for 515 of 534 confirmed cases and faces IS-controlled access blockades in Mambasa that health authorities cannot resolve.
United States (HHS/CDC)
United States (HHS/CDC)
HHS expanded the Ebola entry ban to green-card holders on 5 June, widening a restriction expiring around 17 June against WHO advice. The CDC simultaneously published the R0=2.51 modelling, the sharpest analytical contribution to the response, from a federal bench that holds the NIH and acting CDC director roles in one person.
Imperial College London / Cori and Ferguson
Imperial College London / Cori and Ferguson
Anne Cori and Neil Ferguson place the case-fatality ratio at 30 to 40 per cent and read the 6.8-to-1 suspected-to-confirmed ratio as evidence that the laboratory figure understates true lethality. Many people die before a swab reaches them.